In a COPD exacerbation, which antibiotic class is considered preferred first-line therapy?

In a COPD exacerbation, which antibiotic class is considered preferred first-line therapy?

• A. Cephalosporins
• B. Bactrim (TMP-SMX)
• C. Macrolides
• D. Fluoroquinolones

Answer: (C)

When a COPD patient has an exacerbation that calls for antibiotics, you want a medication that reliably covers the organisms that typically cause these flare-ups and can help reduce airway inflammation. Macrolides fit that need well. They cover the common respiratory pathogens in COPD—Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae—as well as atypicals like Mycoplasma and Chlamydophila. Azithromycin, in particular, offers convenient dosing and may have anti-inflammatory benefits that can help during an exacerbation. In many outpatient cases, a macrolide is chosen first, with alternatives like doxycycline or amoxicillin-clavulanate used based on local resistance patterns and patient factors. Fluoroquinolones are reserved for more severe disease or specific risk factors (such as suspicion of Pseudomonas or treatment failure) because they have broader coverage but come with more adverse effects and resistance concerns. Cephalosporins and TMP-SMX don’t consistently cover the full spectrum of COPD pathogens, especially atypicals, so they’re not preferred first-line in this context.

When a COPD patient has an exacerbation that calls for antibiotics, you want a medication that reliably covers the organisms that typically cause these flare-ups and can help reduce airway inflammation. Macrolides fit that need well. They cover the common respiratory pathogens in COPD—Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae—as well as atypicals like Mycoplasma and Chlamydophila. Azithromycin, in particular, offers convenient dosing and may have anti-inflammatory benefits that can help during an exacerbation. In many outpatient cases, a macrolide is chosen first, with alternatives like doxycycline or amoxicillin-clavulanate used based on local resistance patterns and patient factors. Fluoroquinolones are reserved for more severe disease or specific risk factors (such as suspicion of Pseudomonas or treatment failure) because they have broader coverage but come with more adverse effects and resistance concerns. Cephalosporins and TMP-SMX don’t consistently cover the full spectrum of COPD pathogens, especially atypicals, so they’re not preferred first-line in this context.